These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 34525347)

  • 1. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.
    Woan KV; Kim H; Bjordahl R; Davis ZB; Gaidarova S; Goulding J; Hancock B; Mahmood S; Abujarour R; Wang H; Tuininga K; Zhang B; Wu CY; Kodal B; Khaw M; Bendzick L; Rogers P; Ge MQ; Bonello G; Meza M; Felices M; Huffman J; Dailey T; Lee TT; Walcheck B; Malmberg KJ; Blazar BR; Bryceson YT; Valamehr B; Miller JS; Cichocki F
    Cell Stem Cell; 2021 Dec; 28(12):2062-2075.e5. PubMed ID: 34525347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
    Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies.
    Cichocki F; van der Stegen SJC; Miller JS
    Blood; 2023 Feb; 141(8):846-855. PubMed ID: 36327161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions.
    Lupo KB; Moon JI; Chambers AM; Matosevic S
    Cytotherapy; 2021 Oct; 23(10):939-952. PubMed ID: 34272175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.
    Meng F; Zhang S; Xie J; Zhou Y; Wu Q; Lu B; Zhou S; Zhao X; Li Y
    J Hematol Oncol; 2023 Jun; 16(1):62. PubMed ID: 37316891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C
    Chiu E; Felices M; Cichocki F; Davis Z; Wang H; Tuninga K; Vallera DA; Lee T; Bjordahl R; Malmberg KJ; Valamehr B; Miller JS
    Mol Ther; 2021 Dec; 29(12):3410-3421. PubMed ID: 34174441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer immunotherapy.
    Zhu H; Kaufman DS
    Blood Sci; 2019 Aug; 1(1):4-11. PubMed ID: 35402797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma.
    Cichocki F; Bjordahl R; Goodridge JP; Mahmood S; Gaidarova S; Abujarour R; Davis ZB; Merino A; Tuininga K; Wang H; Kumar A; Groff B; Witty A; Bonello G; Huffman J; Dailey T; Lee TT; Malmberg KJ; Walcheck B; Höpken U; Rehm A; Valamehr B; Miller JS
    Nat Commun; 2022 Nov; 13(1):7341. PubMed ID: 36446823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
    Nianias A; Themeli M
    Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
    Knorr DA; Ni Z; Hermanson D; Hexum MK; Bendzick L; Cooper LJ; Lee DA; Kaufman DS
    Stem Cells Transl Med; 2013 Apr; 2(4):274-83. PubMed ID: 23515118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
    Zhu H; Kaufman DS
    Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
    Goldenson BH; Hor P; Kaufman DS
    Front Immunol; 2022; 13():841107. PubMed ID: 35185932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.
    Zhu H; Blum RH; Bernareggi D; Ask EH; Wu Z; Hoel HJ; Meng Z; Wu C; Guan KL; Malmberg KJ; Kaufman DS
    Cell Stem Cell; 2020 Aug; 27(2):224-237.e6. PubMed ID: 32531207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Into the multiverse of gene edited NK cell-based therapeutic strategies.
    Goldenson BH; Kaufman DS
    Cell Stem Cell; 2021 Dec; 28(12):2041-2043. PubMed ID: 34861144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy.
    Xue D; Lu S; Zhang H; Zhang L; Dai Z; Kaufman DS; Zhang J
    Trends Biotechnol; 2023 Jul; 41(7):907-922. PubMed ID: 36858941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iPSC-Derived Natural Killer Cells for Cancer Immunotherapy.
    Karagiannis P; Kim SI
    Mol Cells; 2021 Aug; 44(8):541-548. PubMed ID: 34373366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies.
    Shankar K; Capitini CM; Saha K
    Stem Cell Res Ther; 2020 Jun; 11(1):234. PubMed ID: 32546200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
    Hermanson DL; Bendzick L; Pribyl L; McCullar V; Vogel RI; Miller JS; Geller MA; Kaufman DS
    Stem Cells; 2016 Jan; 34(1):93-101. PubMed ID: 26503833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.